A recent Reuters article reported on data from 3,046 people with obesity or a BMI of 30 and above who had commercial health plans. It raised a crucial question for employers: Are weight-loss drugs like Ozempic and Wegovy worth the investment? The study found no cost reduction within two years, leading to understandable hesitancy. However, looking beyond short-term data could reveal the true value of covering these medications.
Beyond short-term returns
Assessing the financial impact of weight-loss drugs within two years is limiting. Obesity-related health issues like heart disease and diabetes take time to develop, so savings from preventing these conditions may only appear in the long term. While it might take time to see financial returns, employers focusing on employees with higher health risks or longer tenure may see significant benefits down the road.
Using the most effective medications
The study included a mix of older and newer drugs, which may have impacted the results. Only 46% of patients used newer, more effective options like Ozempic and Wegovy, while others were on older, less effective drugs like Trulicity and Victoza. This mix can skew the results, masking the benefits of the latest treatments. Employers should consider covering only the most effective medications for the right employees to achieve the best outcomes.
Targeted coverage with clear success criteria
To get the best results, weight-loss drugs should be prescribed thoughtfully. Covering them broadly may not yield the cost and health benefits employers hope for. Focusing on high-risk employees—those with severe obesity or related health issues—can drive better outcomes. This targeted approach could lead to substantial health improvements and financial benefits.
Weight-loss medications also require careful management, with adjustments and regular monitoring to ensure effectiveness and prevent waste. According to the study, only 30% of patients adhered to their prescriptions after 12 months. These rates are much lower than seen in clinical studies or my practice. Since the study calculated adherence based on pharmacy claims, we may be missing people who paid cash for the drugs, who stopped due to high copays, or who simply weren’t able to get the medications filled because of the frequent drug shortages that continue to be an issue. Utilizing a medication management program like 9amHealth that offers clinical pharmacy support, tracks adherence supports members in sourcing the drugs for continued therapy, and prevents early discontinuation is essential for maximizing the value of your investment.
Supporting weight loss with lifestyle programs
Covering weight-loss medications alone isn’t enough. These drugs work best when combined with lifestyle and behavioral support. Programs with integrated coaching for exercise, diet, and behavioral changes can boost adherence and lead to better outcomes. It’s possible that the lack of such support in the study contributed to the absence of cost and health benefits. A comprehensive weight management program can help employees maintain progress, avoid side effects, and stay engaged, maximizing the value of the investment.
More than just cost savings: Quality of life and productivity
Weight loss has benefits beyond health, such as better mental health, increased energy, and higher productivity. Although these “intangible” benefits don’t appear in cost analyses, they can improve employee satisfaction and morale. Healthier employees often report greater workplace engagement, fewer absences, and improved performance. Employers should consider these broader benefits when deciding to cover weight-loss drugs.
Partnering with experts for effective weight management
Employers can maximize the impact of weight-loss drugs by working with partners who understand these treatments, know how to identify high-risk employees, and can offer continuous support. With a strategic, evidence-based approach, covering these medications can be a valuable investment in employee health and a healthier workforce overall.